Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 11/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.31 |
| ▸ | GSK3B | P49841 | 2/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | CFTR | P13569 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24985902 | 0.93 | HDAC1 (0.33) | HDAC1HDAC2ABL1GABRA5GSK3B | |
| SCHEMBL24985899 | 0.93 | HDAC1 (0.33) | HDAC1HDAC2ABL1GABRA5GSK3B | |
| SCHEMBL26527289 | 0.92 | GABRA5 (0.31) | ABL1GABRA5MAPK14 | |
| SCHEMBL25116420 | 0.92 | HDAC1 (0.32) | HDAC1HDAC2ABL1GABRA5GSK3B | |
| SCHEMBL25115558 | 0.92 | ABL1 (0.33) | HDAC1HDAC2ABL1GABRA5GSK3B | |
| SCHEMBL25115565 | 0.92 | ABL1 (0.33) | HDAC1HDAC2ABL1GABRA5GSK3B | |
| SCHEMBL25116228 | 0.92 | HDAC1 (0.32) | HDAC1HDAC2ABL1GABRA5GSK3B | |
| SCHEMBL25116022 | 0.92 | HDAC1 (0.32) | HDAC1HDAC2ABL1GABRA5GSK3B | |
| SCHEMBL25117180 | 0.92 | HDAC1 (0.32) | HDAC1HDAC2ABL1GABRA5GSK3B | |
| SCHEMBL25115598 | 0.91 | HDAC1 (0.32) | HDAC1HDAC2ABL1GABRA5GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | HDAC1 996/4885HDAC2 857/4885ABL1 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.